Sign in
Taking peoplePhase 2

EGb 761 for mild cognitive impairment together with cerebrovascular disease

Tests EGb 761 in people with mild cognitive impairment and cerebrovascular disease.

Key facts

Who runs it
National Neuroscience Institute
Where
Singapore1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
EGb 761 in the Syndrome of MCI With Concomitant CVD
Status
Recruiting
Phase
Phase 2
People taking part
134 people, planned
Started
26 Oct 2020
Expected to end
Nov 2026
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Tebonin Forte
Record updated
17 November 2022

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with mild cognitive impairment (mild memory and thinking problems) who also have disease of the brain's blood vessels.

Age
45 to 85 years
Sex
All sexes
Disease stage
Mild cognitive impairment diagnosed by the Petersen criteria and Albert MS criteria, with a Global Clinical Dementia Rating Score of 0.5. Blood vessel disease of the brain means white matter changes (white matter hyperintensities) of Fazekas grade 2 or 3. These must be seen on an MRI scan done up to 12 months before joining, or a CT scan if MRI cannot be done.

Main reasons for not taking part

  • Taking antidepressants, antipsychotics or benzodiazepines during the study
  • Taking acetylcholinesterase inhibitors or NMDA antagonists (dementia drugs) during the study
  • Any reason listed in the drug's product information why EGb 761 must not be used
  • Not able to read and write, or not able to complete the memory and thinking tests

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Patients who have been diagnosed with MCI based on the Petersen criteria and Albert MS criteria
  • Patients who have a Global Clinical Dementia Rating Score of 0.5
  • Patients aged 45 to 85 years at study entry
  • Patients who are literate and able to complete the cognitive evaluations in the opinion of the investigators
  • Patients with the presence of CVD, defined as the presence of white matter hyperintensities (WMH) of Fazekas grade 2 or 3 on MRI brain imaging (done up to 12 months prior to recruitment) or CT scans for patients contraindicated from MRI scans
  • Patients who provide written informed consent to participate in the study

Who cannot take part

  • Participants should not be receiving antidepressants, antipsychotics, benzodiazepines, acetylcholinesterase inhibitors or NMDA antagonists during the study. Additionally, contraindications for EGb 761 as given in the local prescribing information/Summary of Product Characteristics (SmPC) should be observed

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 45 and 85 years old?

This trial is currently available in Singapore.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

EGb 761 has been demonstrated to be useful in improving cognitive and global clinical outcomes in patients with cognitive impairment or dementia, when administered at a daily dosage of 240mg in randomised controlled trials through several neuroprotective mechanisms of action. The study aims to determine the efficacy and safety profile of EGb 761 as a prescribed clinical drug for patients with MCI + CVD.

The 2 groups in the trial

  • Tebonin ForteTreatment being tested

    Treatment: 120mg, twice a day, 52 weeks

  • ControlNo study treatment, for comparison

    No Treatment

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluating the Role of EGb 761 in the Syndrome of Mild Cognitive Impairment With Concomitant Cerebrovascular Disease (MCI + CVD)
Plain-language title
EGb 761 for mild cognitive impairment together with cerebrovascular diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT04525144, who can take part
Record updated
17 November 2022